Findings

What do systematic reviews say?

670 questions · 686 findings · 338 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%

Summary of findings ‐ Ciklavit® vs placebo

Quality of life measures · people with SCD

The review found no eligible studies for this question.

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Pfaffia paniculata vs placebo

Quality of life measures · children with SCD

1 finding from 1 review

Phytomedicines (medicines derived from plants) for sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Tiotropium vs placebo

QoL · people with COPD who have smoked for ≥ 10 pack‐years

Tiotropium showed no clear difference in quality of life (SGRQ) Scale 0 to 100, where 100 represents worst… compared with placebo (high certainty).

1 finding from 1 review

Tiotropium versus placebo for chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 13034 participants
High

Macrolides vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults and children with chronic asthma

1 finding from 1 review

Macrolides versus placebo for chronic asthma 2021 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 802 participants
Very low

Medical or surgical intervention, or both, for gastro‐oesophageal reflux disease vs nil intervention, delayed intervention control, or placebo

Change in quality of life · treatment for asthma in adults and children with asthma and GORD

1 finding from 1 review

Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with… 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1595 participants
Low

Bamlanivimab/etesevimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sotrovimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Regdanvimab vs placebo

Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral gabapentin vs placebo

Change in quality of life · adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 67 participants
Low

Oral hydroxyurea vs placebo

Change in quality of life · children and adults with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral olesoxime vs placebo

Change in quality of life · non‐ambulatory children and adolescents with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 108 participants
Low

Oral creatine vs placebo

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Oral phenylbutyrate vs placebo

Change in quality of life · children with SMA type II

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Subcutaneous somatotropin vs placebo

Change in quality of life · children and adults with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
19 participants
Very low

Intravenous thyrotropin releasing hormone vs placebo

Change in quality of life · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral valproic acid plus acetyl‐L‐carnitine vs placebo

Change in quality of life · non‐ambulatory children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Very low

Oral valproic acid vs placebo

Change in quality of life · ambulatory adults with SMA type III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
28 participants
Moderate

Selective serotonin reuptake inhibitors vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Tricylic antidepressant vs placebo

Change in quality of life · chronic obstructive pulmonary disease (COPD) with depression

1 finding from 1 review

Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Macrolides vs placebo

Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Moderate